Diabetes 68 , 2133 (2018)
Forward Look: Employers should prepare for integrating GLP1 coverage with screening, counseling, and monitoring
Tirzepatide can cause mild gastrointestinal discomfort, including nausea, vomiting, and constipation, particularly during the initial stages of treatment
Eli Lilly is the only official manufacturer of tirzepatide
As many patients view insulin therapy as a last-resort therapy, physicians should instead introduce the concept of insulin at the time of diagnosis
Users of copper peptides have experienced mild irritation like itching, redness, and rashes when applying the different product formats to their skin